Escitalopram in a working population: Results from an observational study of 2378 outpatients in Austria

Human Psychopharmacology

Volumn 22, Issue 4, 2007, Pages 245-251

  Winkler, Dietmar ^a   Pjrek, Edda ^a   Moser, Ulrike ^a   Kasper, Siegfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antidepressants; Escitalopram; Major depression; Sick leave

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ESCITALOPRAM; MILNACIPRAN; MIRTAZAPINE; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; VENLAFAXINE;

ADOLESCENT; ADULT; AGED; ANXIETY DISORDER; ARTICLE; AUSTRIA; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL EXAMINATION; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; FATIGUE; FEMALE; HUMAN; INCIDENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; MOOD DISORDER; MULTICENTER STUDY; NATURALISTIC INQUIRY; NAUSEA; OBSERVATIONAL STUDY; OUTPATIENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; SIDE EFFECT; SWEATING; WORKER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; AUSTRIA; CITALOPRAM; EMPLOYMENT; FEMALE; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; SICK LEAVE;

EID: 34250670758     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.839     Document Type: Article

References (41)

1. Anders M, Tuma I, Rösslerova H. 2006. Escitalopram: post-marketing surveillance in depressed outpatients. Poster Presented at the 14th European Congress of Psychiatry.
2. Auquier P, Robitail S, Llorca PM, Rive B. 2003. Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psychiatry Clin Pract 7: 259-268.
3. Berto P, D'Ilario D, Ruffo P, Di Virgilio R, Rizzo F. 2000. Depression: cost-of-illness studies in the international literature, a review. J Merit Health Policy Econ 3: 3-10.
4. Bielski RJ, Bose A, Chang CC. 2005. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 17: 65-69.
5. Bundesgesetzblatt für die Republik Österreich. 1983. Bundesgesetz vom 2. März 1983 über die Herstellung und das Inverkehrbringen von Arzneimitteln (Arzncimittelgesetz). BGBI. Nr. 185/ 1983.
6. Burke WJ, Gergel I, Bose A. 2002. Fixed-dose trial of the single isomer SSRI escitalopmm in depressed outpatients. J Clin Psychiatry 63: 331-336.
7. Chen F, Larsen MB, Sanchez C, Wiborg O. 2005. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 15: 193-198.
8. Chrisholm D. 2005. Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the world health organization. World Psychiatry 4: 37-44.
9. Corruble E, Puech AJ. 1993. How to improve the risk-benefit ratio of antidepressants. Int Clin Psychopharmacol 8: 237-241.
10. Demyttenaere K, Hemels ME, Hudry J, Annemans L. 2005. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther 27: 111-124.
11. Fernandez JL, Montgomery S, Francois C. 2005. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 23: 155-167.
12. Francois C, Toumi M, Aakhus AM, Hansen K. 2003. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur J Health Econ 4: 12-19.
13. Goodman WK, Bose A, Wang Q. 2005. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 87: 161-167.
14. Gorman JM, Korotzer A, Su G. 2002. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 7: 40-44.
15. Guy W. 1976. ECDEU assessment manual for psychopharmacology. US Department of Health, Education and Welfare publication (ADM) 76-338. National Institute of Mental Health, Rockville, MD.
16. Hakkarainen H, Hattab JR, Venulet J. 1984. Phase IV research by pharmaceutical companies. Pharmacopsychiatry 17: 168-175.
17. Hauptverband der Österreichisches Sozialversicherungsträger. 2002. Handbuch der Österreichischen Sozialversicherung 2002. Österreichische Sozialversicherung, Wien.
18. Hemels ME, Kasper S, Walter E, Einarson TR. 2004a. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Curr Med Res Opin 20: 869-878.
19. Hemels ME, Kasper S, Walter E, Einarson TR. 2004b. Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression. Ann Pharmacother 38: 954-960.
20. Kasper S, Stein DJ, Loft H, Nil R. 2005. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 186: 222-226.
21. Kasper S, Spadone C, Verpillat P, Angst J. 2006. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol 21: 105-110.
22. Kennedy SH, Andersen HF, Lam RW. 2006. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a recta-analysis. J Psychiatry Neurosci 31: 122-131.
23. Kessler RC, Greenberg PE, Mickelson KD, Meneades LM, Wang PS. 2001. The effects of chronic medical conditions on work loss and work cutback. J Occup Environ Med 43: 218-225.
24. Klein N, Wiesegger G, Attarbaschi T, et al. 2004. A naturalistic observational study of escitalopram in the treatment of depression and anxiety disorder in adult outpatients. Rom J Psychopharmacol 4: 1-9.
25. Lepola UM, Loft H, Reines EH. 2003. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 18: 211-217.
26. Linden M, Baler D, Beitinger H, et al. 1994. Leitlinien zur Durchführung von Anwendungsbeobachtungen (AWB) in der Psychopharmakothempie. Nervenarzt 65: 638-644.
27. Llorca PM, Azorin JM, Despiegel N, Verpillat P. 2005. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 59: 268-275.
28. Möller HJ, Langer S, Fuger J, Schmauß M. 2005. Behandlung der Depression mit Escitalopram: Ergebnisse einer großen Anwendungsbeobachtung. DGPPN: Berlin, Germany.
29. Moore N, Verdoux H, Fantino B. 2005. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 20: 131-137.
30. Pjrek E, Winkler D, Stastny J, Praschak-Rieder N, Willeit M, Kasper S. 2007. Escitalopram in seasonal affective disorder: results of an open trial. Pharmacopsychiatry 40: 20-24.
31. Rapaport MH, Bose A, Zheng H. 2004. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 65: 44-49.
32. Rush AJ, Bose A. 2005. Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depress Anxiety 21: 26-32.
33. Smit F, Cuijpers P, Oostanbrink J, Batelaan N, de Graaf R, Beckman A. 2006. Costs of nine common mental disorders: implications for curative and preventive psychiatry. J Ment Health Policy Econ 9: 193-200.
34. Sobocki P, Jonsson B, Angst J, Rehnberg C. 2006. Cost of depression in Europe. J Ment Health Policy Econ 9: 87-98.
35. SPSS Inc. 1989-2001. SPSS for Windows. Chicago, IL, USA.
36. Stahl SM, Gergel I, Li D. 2003. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 64: 1322-1327.
37. Statistik Austria. 2003. Statistisches Jahrbuch. http://www.statistik.at
38. Wade A, Despiegel N, Reines E. 2002. Long-term treatment of depression with escitalopram is safe and well-tolerated. Eur Neuropsychopharmacol 12(Suppl 3): 232-233.
39. Wade AG, Toumi I, Hemels ME. 2005a. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin Ther 27: 486-496.
40. Wade AG, Toumi I, Hemels ME. 2005b. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin 21: 631-642.
41. Winider D, Kasper S. 2004. Escitalopram. Arzneimitteltherapie 22: 97-102.